The FDA recently released information regarding reduced activity of Bebtelovimab against certain emerging Omicron subvariants. Bebtelovimab is NOT expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.
As of November 5th, subvariant BQ.1 and BQ.1.1 are responsible for 28.8% and 23.5% of New York State Omicron subvariants, respectively. Currently, the likelihood that Bebtelovimab will be efficacious is < 50%. The image below depicts how rapidly these two variants are becoming predominate, meaning Bebtelovimab will only become even less efficacious moving forward.
